I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Gynaecology

Gynecology

Diseases
Endometriosis Pre-Eclampsia

Preview the latest medical materials

Sign up or login to unlock the full suite of MEDICALLY features
Jan 30 / Roche
Reference range for Elecsys sFlt-1/PlGF ratio in a diverse U.S population
The sFlt-1/PlGF ratio test is used for the clinical prediction of preeclampsia in many countries worldwide but has not been widely adopted in the US. This study aimed to determine the reference range for the Roche Elecsys sFlt-1/PlGF ratio (electrochemiluminescent immunoassays) in a racially and ethnically diverse healthy US population of pregnant women at 23+0 - 34+6 gestational weeks.
Gynaecology Pre-Eclampsia SMFM-Pregnancy-Meeting-2025

Sign up or login to unlock the full suite of MEDICALLY features
Nov 18 / Roche
Cost Consequence Analysis of Using the Elecsys Anti-Müllerian Hormone Plus Immunoassay as Part of Polycystic Ovary Syndrome Assessment in the United Kingdom
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder amongst women. Diagnosis is based on the Rotterdam criteria, which requires at least two of the following criteria to be met: oligo-anovulation, clinical/biochemical hyperandrogenism and polycystic ovarian morphology (PCOM). PCOM detection has previously relied on transvaginal ultrasound, which is limited by diagnostic performance, accessibility and inter- and intra-operator variability. Anti-Müllerian hormone (AMH) testing is a new recommended alternative. This health economic study assessed the impact of using the Elecsys® AMH Plus immunoassay to detect PCOM for the diagnosis of PCOS in the United Kingdom.
Gynaecology ISPOR-EUROPE-2024

Sign up or login to unlock the full suite of MEDICALLY features
Oct 23 / Roche
Anti-Müllerian hormone to determine polycystic ovarian morphology: a sub-analysis of the APHRODITE study in an Asian population
An exploratory analysis of a cutoff for anti-Müllerian hormone (AMH) to identify PCOM with high sensitivity in Asian and Japanese women with PCOS phenotype A (the only phenotype diagnosed as PCOS in Japan).
Gynaecology ASRM-2024
View full list of congress materials
Upcoming congresses
Access to Roche and Genentech's latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.